Compile Data Set for Download or QSAR
Report error Found 59 of affinity data for UniProtKB/TrEMBL: P01009
TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629202(US20230339915, Compound 80)
Affinity DataIC50: 2.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629221(US20230339915, Compound 164 | Synthesis of 4-(1-(4...)
Affinity DataIC50: 2.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629222(US20230339915, Compound 165 | Synthesis of 4-(2-(I...)
Affinity DataIC50: 2.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629223(US20230339915, Compound 167)
Affinity DataIC50: 2.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629225(US20230339915, Compound 170)
Affinity DataIC50: 2.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629218(US20230339915, Compound 148)
Affinity DataIC50: 2.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629189(US20230339915, Compound 57)
Affinity DataIC50: 2.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629227(US20230339915, Compound 177 | Synthesis of 4-(6-ch...)
Affinity DataIC50: 2.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629228(US20230339915, Compound 178 | Synthesis of 4-(4-ch...)
Affinity DataIC50: 2.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629219(US20230339915, Compound 149)
Affinity DataIC50: 3.50E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629224(US20230339915, Compound 168)
Affinity DataIC50: 3.50E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629226(US20230339915, Compound 172)
Affinity DataIC50: 3.50E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629203(US20230339915, Compound 89)
Affinity DataIC50: 3.50E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629190(US20230339915, Compound 58)
Affinity DataIC50: 3.50E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629207(US20230339915, Compound 97)
Affinity DataIC50: 3.50E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629183(US20230339915, Compound 22)
Affinity DataIC50: 3.50E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629220(US20230339915, Compound 150 | 6-(1-(4-fluoro-3-met...)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629213(US20230339915, Compound 134)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629217(US20230339915, Compound 145)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629216(US20230339915, Compound 141)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629215(US20230339915, Compound 140 | 6-(1-(4-fluoro-3-met...)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629214(US20230339915, Compound 139 | Synthesis of trans-3...)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629209(US20230339915, Compound 104)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629229(US20230339915, Compound 181)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629230(US20230339915, Compound 184 | 1-(1-(4-fluorophenyl...)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629231(US20230339915, Compound 186)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629232(US20230339915, Compound 190)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629233(US20230339915, Compound 213 | 3-(1-(4-fluoro-3-met...)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629234(US20230339915, Compound 215 | 3-[1-(4-fluoro-3-met...)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629235(US20230339915, Compound 216 | N-((3-(1-(4-fluoro-3...)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629236(US20230339915, Compound 217 | 1-(4-fluoro-3-methyl...)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629237(US20230339915, Compound 219)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629238(US20230339915, Compound 220)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629196(US20230339915, Compound 69)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629181(US20230339915, Compound 12)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629182(US20230339915, Compound 17)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629184(US20230339915, Compound 27)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629185(US20230339915, Compound 31)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629186(US20230339915, Compound 32)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629187(US20230339915, Compound 33)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629188(US20230339915, Compound 37)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629191(US20230339915, Compound 59)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629192(US20230339915, Compound 60)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629193(US20230339915, Compound 61)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629194(US20230339915, Compound 63)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629195(US20230339915, Compound 68)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629212(US20230339915, Compound 130)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629197(US20230339915, Compound 71)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629198(US20230339915, Compound 75)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

TargetAlpha-1-antitrypsin(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM629199(US20230339915, Compound 77)
Affinity DataIC50: 5.00E+3nMAssay Description:Assay Protocol: Pre-Incubation of Z-AAT with Compounds1. 7.5 μL of Z-AAT (20 nM) was incubated with compounds 1-227 in a GCA plate for 1 hour at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 59 total ) | Next | Last >>
Jump to: